Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Cash Flow Statement 
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Biogen Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Net income 1,134,900 1,058,700 218,500 (20,500) 318,000 1,025,500 404,600 357,600 703,900 1,606,400 1,392,600 1,439,700 1,545,900 1,494,100 1,408,800 944,900 1,442,900 915,000 1,171,200 (166,300) 1,226,100 862,800 747,500
Depreciation and amortization 120,700 134,800 143,100 134,700 133,200 117,200 102,600 109,700 114,700 112,900 119,900 113,000 329,500 117,000 121,100 329,700 346,500 171,500 168,900 209,000 177,400 182,600 512,000
Impairment of intangible assets 43,400 541,600 44,300 190,400 19,300
Excess and obsolescence charges related to inventory 16,000 24,100 281,500 131,100 28,200 (3,600) 11,900
Acquired in-process research and development 18,000 75,000 27,500 75,000 10,000 120,000
Share-based compensation 63,600 55,700 67,600 58,800 55,700 54,100 70,000 49,000 33,500 48,100 67,700 38,400 45,900 52,300 45,700 38,500 37,300 38,300 43,400 30,600 30,100 30,300 37,000
Gain on interest rate swap 3,300 (3,300)
Contingent consideration (2,100) (4,500) (7,100) (1,600) (15,600) 300 (33,800) (62,800) (29,000) 10,100 (4,600) 2,600 (57,800) (20,000) 11,500 79,300 (87,900) 1,900 (5,600) 1,500 61,200
(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations (92,500) (40,200) (17,700) (2,300) 115,500
Deferred income taxes (92,300) (48,500) 1,000 323,300 (127,300) (607,800) (15,000) (62,900) 31,700 143,300 36,900 38,700 (43,200) (156,400) 228,000 153,100 12,600 (110,500) 53,100 131,400 (19,200) (96,600) 76,100
(Gain) loss on strategic investments (109,000) 78,200 191,100 116,300 426,900 (154,000) 437,600 (723,600) 81,500 (101,700) 62,000 42,500 9,400 175,800 (375,000)
(Gain) loss on equity method investments (5,900) 3,300 (17,700) (1,100) (34,300) 18,200 (18,000) 13,100 (15,200) 16,800
Gain on sale of equity interest in Samsung Bioepis (1,505,400)
Gain on sale of building (503,700)
Other 35,600 68,900 43,300 37,700 60,400 44,300 59,800 21,100 26,400 54,800 28,900 65,600 59,800 40,400 50,700 (900) (114,300) 14,400 31,700 96,400 (7,800) 55,400 18,100
Accounts receivable (42,200) 20,200 (87,500) 167,000 (53,700) 174,300 37,200 138,500 133,100 (30,400) (238,400) 71,200 500 133,700 (136,600) 48,800 (66,800) (53,200) (134,000) (209,800) 75,400 (105,500) (195,700)
Due from anti-CD20 therapeutic programs 20,600 (46,500) 22,900 (12,300) 22,200 (52,500) 43,800 113,700 (86,100) 70,500 78,600 (7,900) (24,800) (30,600)
Inventory (95,000) (100,700) (142,600) (139,800) (128,800) (81,300) (112,500) (45,700) (82,400) (126,000) (62,200) (66,500) (61,400) (20,300) 129,000 (20,200) 8,200 (42,700) 2,600 75,800 (85,000) (39,100) (46,200)
Accrued expense and other current liabilities (1,700) 1,095,600 (461,600) 147,900 (54,900) 95,200 (283,600) (218,700) 814,300 (94,000) (347,400) 349,300 107,000 (77,700) (138,400) 364,800 87,400 135,100 (121,800) 277,100 (52,200) 231,900 (684,200)
Income tax assets and liabilities (34,300) (167,800) 101,900 (29,700) 89,000 106,700 64,800 (82,800) (489,300) 281,600 223,000 (48,500) (242,300) 136,600 170,300 6,100 132,200 (74,200) 257,600 1,133,400 285,200 80,400 (195,100)
Other changes in operating assets and liabilities, net 149,900 79,600 (213,600) (56,900) 9,700 (16,400) (80,900) (40,100) (106,900) (8,600) 18,500 (37,700) 44,100 121,400 (171,100) (48,700) (89,700) 28,700 (20,000) (60,800) (62,900) (153,000) (34,300)
Changes in operating assets and liabilities, net (2,700) 880,400 (780,500) 76,200 (116,500) 226,000 (331,200) (135,100) 182,700 93,100 (327,900) 259,900 (176,900) 263,100 (146,800) 350,800 71,300 (6,300) (15,600) 1,215,700 160,500 14,700 (1,155,500)
Adjustments to reconcile net income to net cash flows from operating activities (473,900) (322,200) (56,700) 858,800 487,300 201,800 364,400 (724,700) 477,200 342,100 74,700 520,500 149,000 469,900 50,700 950,500 293,000 184,300 285,900 1,684,600 402,200 306,400 (512,300)
Net cash flow provided by operating activities 661,000 736,500 161,800 838,300 805,300 1,227,300 769,000 (367,100) 1,181,100 1,948,500 1,467,300 1,960,200 1,694,900 1,964,000 1,459,500 1,895,400 1,735,900 1,099,300 1,457,100 1,518,300 1,628,300 1,169,200 235,200
Purchases of property, plant and equipment (59,100) (36,900) (57,900) (51,600) (42,000) (71,900) (92,600) (86,000) (84,100) (105,000) (149,700) (110,400) (90,100) (186,900) (127,100) (225,900) (163,200) (186,800) (194,700) (230,600) (229,100) (197,700) (210,000)
Proceeds from sales and maturities of marketable securities 1,643,200 917,900 543,600 1,377,300 575,400 633,500 819,200 2,058,700 1,360,800 1,490,600 2,389,300 2,139,400 611,800 1,766,600 1,489,200 1,179,000 1,192,000 2,733,800 4,068,900 1,093,300 888,100 1,700,200 1,884,300
Purchases of marketable securities (494,300) (1,178,100) (1,133,500) (1,436,100) (745,700) (713,600) (913,300) (1,748,600) (895,200) (2,069,200) (1,684,700) (1,200,500) (1,977,000) (1,250,100) (825,000) (1,601,000) (1,319,500) (2,855,100) (1,919,200) (1,261,300) (1,557,900) (1,279,300) (1,256,700)
Proceeds from sale of equity interest in Samsung Bioepis 990,300
Proceeds from sale of building 582,600
Contingent consideration paid related to Fumapharm AG acquisition (300,000) (300,000) (300,000) (300,000) (600,000) (300,000) (300,000) (300,000) (300,000)
Acquisition of Nightstar Therapeutics plc, net of cash acquired (744,400)
Purchase of Sangamo Therapeutics, Inc. stock (141,800)
Purchase of Denali Therapeutics Inc. stock (423,700)
Purchase of Sage Therapeutics, Inc. stock (441,000)
Proceeds from divestiture of Hillerød, Denmark manufacturing operations 28,100 923,700
Acquired in-process research and development (18,000) (75,000) (27,500) (75,000) (10,000) (120,000)
Acquisitions of intangible assets (1,900) (16,900) (1,900) (15,000) (37,000) (155,000) (3,000) (65,000) (50,100) (5,100) (855,200)
Purchase of Ionis Pharmaceuticals, Inc. stock 800 (463,700)
Proceeds from sales of strategic investments 2,300 91,200 74,400 500 3,300 166,300 309,700
Investment in Samsung Bioepis (676,600)
Other (200) 2,200 (200) 12,300 (1,400) (700) 2,700 (8,900) (10,200) (7,300) (500) 31,600 (600) (5,700) 1,700 (800) (1,700) 1,300 1,600 (5,900) 2,200 (700) (6,600)
Net cash flow (used in) provided by investing activities 1,672,200 693,500 (648,000) (112,700) (233,600) (152,700) (64,700) (166,400) (52,400) (832,700) 442,900 708,400 (365,900) (110,800) 238,800 (1,625,300) (619,100) (1,148,500) 1,346,600 (769,500) (1,246,800) (202,600) (744,200)
Purchases of treasury stock (250,000) (500,000) (750,000) (450,000) (600,000) (400,000) (1,250,000) (2,808,900) (2,220,200) (2,093,100) (717,900) (2,401,500) (655,800) (1,352,600) (2,750,000) (250,000) (781,800) (583,600)
Payments related to issuance of stock for share-based compensation arrangements, net 5,700 9,300 (20,800) 7,600 5,900 12,900 (27,100) 7,200 7,400 10,400 (29,600)
Repayment of borrowings and premiums paid (1,002,200) (700) (169,300)
Proceeds from borrowings 100 2,967,300
Repayment of borrowings (1,500,000) (3,200) (557,700) (3,200)
Cash proceeds from settlement of swap (3,300) 3,300
Net contribution (distribution) to noncontrolling interest 100 11,900 200 400 (94,800) (100) (70,900) 4,300 500 2,000 (38,900) (134,100)
Net cash contribution to Bioverativ Inc. (302,700)
Contingent consideration payments (58,200) (3,000)
Other (5,500) 7,300 4,100 1,800 (2,400) (31,900) 11,400 (8,300) 3,900 14,500 4,500 (23,300) 28,900 21,500 (23,500) (26,700) 23,100 600 (18,600) (13,300) (16,300) 30,800 (15,100)
Net cash flow used in financing activities (1,251,900) (471,500) (16,500) 9,800 (746,500) (564,500) (785,000) (401,100) (1,312,900) (1,313,400) (2,245,300) (2,116,400) (689,000) (2,375,700) (679,300) (1,437,000) 25,100 (2,791,500) (268,600) (708,100) (19,500) (751,000) (901,400)
Effect of exchange rate changes on cash and cash equivalents (52,300) (61,200) (9,400) (15,800) (25,400) 14,400 (33,000) 41,000 24,100 (8,800) 12,700 17,600 (19,500) 2,700 (400) 4,800 (5,400) (17,100) (900) (15,000) 16,600 29,900 7,900
Net increase (decrease) in cash and cash equivalents 1,029,000 897,300 (512,100) 719,600 (200,200) 524,500 (113,700) (893,600) (160,100) (206,400) (322,400) 569,800 620,500 (519,800) 1,018,600 (1,162,100) 1,136,500 (2,857,800) 2,534,200 25,700 378,600 245,500 (1,402,500)

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Cash flow statement item Description The company
Net cash flow provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Biogen Inc. net cash flow provided by operating activities increased from Q1 2022 to Q2 2022 but then slightly decreased from Q2 2022 to Q3 2022.
Net cash flow (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Biogen Inc. net cash flow (used in) provided by investing activities increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Net cash flow used in financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Biogen Inc. net cash flow used in financing activities decreased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.